AQAL Capital

AQAL Capital does not look like the firms most healthcare AI founders have pitched before, and that is the entire point. Operating from Munich under the banner of Integral Investing, AQAL filters every prospective investment through alignment with the United Nations Sustainable Development Goals while simultaneously demanding the kind of exponential-technology profile that more conventional venture firms reserve for their largest growth bets. The result is a fund that will look at a clinical AI platform alongside a quantum computing company and a renewable energy play and treat all three as expressions of the same underlying philosophy. For physician founders contemplating European seed capital with a thesis-driven anchor, AQAL is one of the more distinctive options on the continent.

The Integral Investing framework is more than branding. AQAL constructs the framework around three interlocking criteria: mission alignment with the SDGs, scalability that can absorb capital and produce category-defining outcomes, and exponential technology defined as compute, AI, quantum, biotech, and adjacent platforms whose performance curves bend rather than creep. Health enters the thesis as one of several mandates rather than the dominant one, which means that medical devices, digital health, and AI/ML in healthcare are evaluated against the same standard as the firm’s bets in renewables or planetary science. Practically, this filters out incremental healthcare software and steers the fund toward platforms where the underlying technology, regulatory pathway, or business model would have been implausible five years ago. Founders should expect questions less about gross margin trajectory and more about why the company exists in 2026 rather than 2016, and what part of the technology stack makes that timing inevitable.

The portfolio reflects this breadth. Penumbra, a neurovascular and peripheral medical device company, is the marquee healthcare reference and signals a willingness to engage with hard regulatory pathways and physical product. Green Spot Technologies works in food fermentation and circular bioeconomy, demonstrating the SDG layer of the thesis in a non-healthcare context. CrowdSmart applies AI to investment decision-making itself. XO Life is a patient-data platform sitting at the intersection of digital health and real-world evidence, the closest analogue in the portfolio to where most healthcare AI founders will be pitching. Entelios and Conject extend the firm’s reach into energy demand response and construction software respectively. Taken together, the portfolio paints AQAL as a generalist exponential-tech investor that takes occasional, conviction-led healthcare bets rather than a sector specialist.

Check sizes typically run between one and five million dollars, placing AQAL squarely in seed and Series A territory. The fund will lead or co-invest, which gives founders flexibility on syndicate construction, and the European base means the firm is well positioned to anchor or co-anchor rounds that include other German, French, and broader EU investors. There is no published revenue requirement, which is consistent with a deep-tech and frontier-technology orientation; AQAL is comfortable underwriting science risk and pre-revenue commercial risk where the technology and mission justify it. For founders running US-led rounds, AQAL has invested across Germany, the United States, and France, so a transatlantic syndicate is workable, but the fund is not a stand-in for a US lead and is best approached when European angle, talent, or regulatory presence is genuinely part of the plan.

The firm is led by co-founders Mariana Bozesan and Tom Schulz. Bozesan is the public face of the Integral Investing methodology and has written extensively on aligning capital with planetary-scale outcomes; founders should expect that the framework is not a marketing layer but the actual decision rubric. Schulz partners on the operational and investment side. Decision-making is concentrated, which has the practical benefit of fast no’s and fewer committee dynamics, but it also means that conviction has to be built with a small number of people who care deeply about the worldview behind a company, not only the financial profile.

Warm introductions through other Integral Investing or impact-aligned investors carry the most weight, as do referrals from existing portfolio founders, particularly those at the intersection of deep tech and mission alignment. European deep-tech investors, exponential-technology funds, and SDG-focused family offices are the natural referral surface. Cold inbound is unlikely to convert without a thesis-aligned narrative; founders who pitch AQAL on financials alone tend to be filtered out early. A short memo that explicitly addresses which SDGs the company advances and which exponential-technology curve it sits on will materially improve the response rate.

Founders should approach AQAL when the company is genuinely mission-aligned and not retrofitting impact language onto a conventional pitch, when the technology is exponential rather than incremental, and when the round is between one and five million dollars at seed or Series A. AQAL is not the right fit for founders who want a passive financial backer or who are uncomfortable articulating why their work matters at a planetary level. For the right healthcare AI company, particularly one with a credible regulatory or platform moat, AQAL offers something rare in European venture: a fund that will engage substantively with the why of a company, not just the how.